The Global Atrophic Vaginitis Treatment Market Growth Accelerated By Increasing Prevalence Of Postmenopausal Symptoms
Atrophic Vaginitis Treatment Market |
Atrophic vaginitis is a condition
that commonly occurs in postmenopausal women characterized by thinning, drying,
and inflammation of the vaginal walls due to decrease in estrogen levels.
Products used in the treatment of atrophic vaginitis include creams, tablets,
rings, and gels that help lubricate and moisturize the vaginal lining. With
rapidly aging female population and rising number of women opting for hormone
replacement therapy, the use of such atrophic vaginitis treatment products is
increasing. The global Atrophic Vaginitis Treatment Market is estimated to be
valued at US$ 658.33 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over
the forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
One of the key trends driving the
growth of the atrophic vaginitis treatment market is increasing prevalence of
postmenopausal symptoms among women. With rising age, majority of women
experience vaginal dryness, itching, irritation or pain during sexual intercourse
due to decreased estrogen levels postmenopause. This makes them more prone to
atrophic vaginitis. As per estimates, around 50-60% of postmenopausal women
suffer from atrophic vaginitis worldwide. Growing health awareness about
management of postmenopausal symptoms and availability of effective treatment
options is encouraging more women to seek medical help. This is anticipated to
fuel demand for atrophic vaginitis drugs and devices over the forecast period.
Segment Analysis
The global atrophic vaginitis
treatment market is segmented on the basis of treatment type and distribution
channel. Based on treatment type, the market is categorized into local estrogen
therapy, systemic estrogen hormone therapy, non-hormonal therapy and others.
The local estrogen therapy segment holds the largest market share owing to its
effectiveness and fewest side effects. The segment includes vaginal estrogen
products such as creams, tablets, and rings.
Key Takeaways
The global
Atrophic Vaginitis Treatment market is expected to witness high growth.
Regional analysis related content comprises
The North America region
dominates the global atrophic vaginitis treatment market and is expected to
continue its dominance during the forecast period. This is attributed to the
developed healthcare infrastructure and rising prevalence of menopause in
countries like the US and Canada. Additionally, presence of key players and
availability of advanced treatment options in the region are supplementing
market growth.
Key players
Key players operating in the
atrophic vaginitis treatment market are Pfizer Inc., TherapeuticsMD Inc.,
Allergan plc (AbbVie Inc.), Duchesnay USA, Novo Nordisk A/S, Merck & Co.,
Inc., Endoceutics Inc., Bausch Health Companies Inc., Mylan N.V., Teva
Pharmaceutical Industries Ltd.
Pfizer Inc. offers vagifem
tablets and uses it as an estrogen replacement therapy for treating vaginal
dryness during menopause. TherapeuticsMD Inc. provides Imvexxy which is
estradiol vaginal inserts for treating moderate-to-severe dyspareunia.
Get More Insights Here
https://www.newswirestats.com/atrophic-vaginitis-treatment-market-size-share-growth-outlook-2023/
Comments
Post a Comment